Besides enhancing phagocytosis via inhibiting the interaction between CD47 and SIRPa, anti-CD47 nanobodies might offer a targeted approach to deliver transgenes to tumor cells expressing CD47. This evidence concerns the gene SIRPA and neoplasm.